论文部分内容阅读
目的:探讨甲状腺素治疗扩张型心肌病患者心力衰竭的疗效及其安全性。方法:选择扩张型心肌病心功能Ⅱ~Ⅳ级患者62例,随机分为治疗1组(n=32)和治疗两组(n=30),治疗两组在常规治疗的基础上加用甲状腺素,比较各组治疗前后甲状腺功能、心脏彩超、心功能改善情况。结果:两组治疗前各项指标差异无统计学意义。治疗后治疗组FT3改善显著(P<0.01),和治疗1组比较差异亦有统计学意义(P<0.05);FT4、TSH变化不显著。治疗两组心脏功能改善更加显著(P<0.01)。治疗两组未出现甲状腺素替代的不良反应。结论:甲状腺素在扩张型心肌病心力衰竭中的使用有效且安全。
Objective: To investigate the efficacy and safety of thyroxine for heart failure in patients with dilated cardiomyopathy. Methods: Sixty-two patients with grade Ⅱ ~ Ⅳ dilated cardiomyopathy were randomly divided into treatment group (n = 32) and treatment group (n = 30). The two groups were treated with thyroid Su, compared thyroid function before and after treatment, echocardiography, cardiac function improvement. Results: There was no significant difference between the two groups before treatment. After treatment, the treatment group FT3 improved significantly (P <0.01), and the treatment group 1 difference was also statistically significant (P <0.05); FT4, TSH change was not significant. The improvement of cardiac function in the two groups was more significant (P <0.01). There was no adverse reaction to thyroxine replacement in the two groups. Conclusion: The use of thyroxine in heart failure of dilated cardiomyopathy is effective and safe.